IL2 and renal cell carcinoma: For Renal Cell Carcinoma (RCC), thirty-seven patients with progressive, MUC1-positive tumors received TG4010 108 pfu/injection weekly for 6 weeks, then every 3 weeks until progression, when TG4010 was continued in combination with interferon-α2a and interleukin-2.